title: Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
abstract: OBJECTIVE
  To determine the longitudinal response of HIV in the cerebrospinal fluid (CSF) to highly active antiretroviral therapy (HAART) and to investigate the levels of indinavir penetrating into the CSF.
  
  
  METHODS
  Open study of HIV-infected subjects naive to therapy with protease inhibitors.
  
  
  METHODS
  Tertiary care referral center.
  
  
  METHODS
  Twenty-five participants were begun on indinavir, nevirapine, zidovudine, and lamivudine.
  
  
  METHODS
  Lumbar punctures were performed prior to therapy and 2 and 6 months after beginning therapy. Plasma and CSF were assayed for routine cell counts, chemistries, HIV load and indinavir levels.
  
  
  RESULTS
  Twenty-two subjects had CSF HIV RNA level data available at all three time points, three others at baseline and 2 months. At month 2 of therapy, nine of 25 (36%) subjects had CSF HIV RNA levels > 50 HIV RNA copies/ml. By 6 months, all 22 subjects had CSF HIV RNA levels < 50 HIV RNA copies/ml. CSF white blood cell counts fell from a baseline mean of 5.3 x 10(6)/l to 1.9 x 10(6)/l (P = 0.013) at 6 months. Plasma indinavir levels declined rapidly while CSF levels remained stable throughout the 8-h dosing interval. The median CSF indinavir level was 71 ng/ml, approximating the upper limit of the 95% inhibitory concentration for indinavir against HIV-1.
  
  
  CONCLUSIONS
  CSF HIV RNA levels cannot be expected to fall below 50 HIV RNA copies/ml even after 2 months of therapy on HAART. Prolonged therapy may be required to suppress HIV levels within the central nervous system.
authors.affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland 20892, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Polis
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Suzman
authors.forename: Christian P
authors.initials: CP
authors.lastname: Yoder
authors.forename: Jean M
authors.initials: JM
authors.lastname: Shen
authors.forename: JoAnn M
authors.initials: JM
authors.lastname: Mican
authors.forename: Robin L
authors.initials: RL
authors.lastname: Dewar
authors.forename: Julia A
authors.initials: JA
authors.lastname: Metcalf
authors.forename: Judith
authors.initials: J
authors.lastname: Falloon
authors.forename: Richard T
authors.initials: RT
authors.lastname: Davey
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Kovacs
authors.forename: Mark B
authors.initials: MB
authors.lastname: Feinberg
authors.forename: Henry
authors.initials: H
authors.lastname: Masur
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Piscitelli
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005500:Follow-Up Studies; D015658:HIV Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D007958:Leukocyte Count; D012367:RNA, Viral / Q000097:blood / Q000134:cerebrospinal fluid*; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019469:Indinavir